Is Kalaris Therapeutics Inc overvalued?

Kalaris Therapeutics Inc (KLRS) — key valuation metrics and fundamentals.

No verdict

Price

$1.57

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$37.5M

Dividend yield

0.0%

Return on equity

-68.8%

Sector

Healthcare

Fair value compares KLRS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.

Related stocks